Produção Nacional
Revisado por pares
Human Tubal-Derived Mesenchymal Stromal Cells Associated with Low Level Laser Therapy Significantly Reduces Cigarette Smoke–Induced COPD in C57BL/6 mice
2015; Public Library of Science; Volume: 10; Issue: 8 Linguagem: Inglês
10.1371/journal.pone.0136942
ISSN1932-6203
AutoresJean Pierre Schatzmann Peron, Auriléia Aparecida de Brito, Mayra Pelatti, Wesley Nogueira Brandão, Luana Beatriz Vitoretti, Flavia R. Greiffo, Elaine Cristina da Silveira, Manuel Carneiro Oliveira-Junior, Mariângela Maluf, Lucila Evangelista, Silvio Halpern, Marcelo Gil Nisenbaum, P.M. Perin, Carlos Eduardo Czeresnia, Niels Olsen Saraiva Câmara, Flávio Aimbire, Rodolfo P. Vieira, Mayana Zatz, Ana Paula Ligeiro de Oliveira,
Tópico(s)Chronic Obstructive Pulmonary Disease (COPD) Research
ResumoCigarette smoke-induced chronic obstructive pulmonary disease is a very debilitating disease, with a very high prevalence worldwide, which results in a expressive economic and social burden. Therefore, new therapeutic approaches to treat these patients are of unquestionable relevance. The use of mesenchymal stromal cells (MSCs) is an innovative and yet accessible approach for pulmonary acute and chronic diseases, mainly due to its important immunoregulatory, anti-fibrogenic, anti-apoptotic and pro-angiogenic. Besides, the use of adjuvant therapies, whose aim is to boost or synergize with their function should be tested. Low level laser (LLL) therapy is a relatively new and promising approach, with very low cost, no invasiveness and no side effects. Here, we aimed to study the effectiveness of human tube derived MSCs (htMSCs) cell therapy associated with a 30mW/3J—660 nm LLL irradiation in experimental cigarette smoke-induced chronic obstructive pulmonary disease. Thus, C57BL/6 mice were exposed to cigarette smoke for 75 days (twice a day) and all experiments were performed on day 76. Experimental groups receive htMSCS either intraperitoneally or intranasally and/or LLL irradiation either alone or in association. We show that co-therapy greatly reduces lung inflammation, lowering the cellular infiltrate and pro-inflammatory cytokine secretion (IL-1β, IL-6, TNF-α and KC), which were followed by decreased mucus production, collagen accumulation and tissue damage. These findings seemed to be secondary to the reduction of both NF-κB and NF-AT activation in lung tissues with a concomitant increase in IL-10. In summary, our data suggests that the concomitant use of MSCs + LLLT may be a promising therapeutic approach for lung inflammatory diseases as COPD.
Referência(s)